Fig. 2.
Fig. 2. Binding of E2 to HUVECs and modulation of the effects of E2 by various compounds. / (A) Saturation curves of the binding of [3H]E2 to cell membranes, alone or in the presence of 100 nM TMX or 100 nM ICI182780. Vertical bars represent SD values. (Inset) Western blot analysis of nuclear (N) and membrane (M) homogenates (10 and 20 μg/lane, respectively), reacted with anti-ERβ antibodies. Molecular mass markers are shown on the right side. (B) Effect of TMX, ICI182780, or HU-210 (100 nM each), of SR141716, CBD, or CAPS (2 μM each), ofl-NAME (400 μM) or of EGTA-am (50 μM) on the activation of AMT by 100 nM E2 or 100 nM E2-BSA (100% = 25 ± 3 pmol × minute−1 × mg protein−1). (C) Effect of the same treatments discussed in panel B on the release of NO and the intracellular calcium ([Ca2+]i) of HUVECs. Values are reported as means ± SD. In all panels, *P < .01 compared with untreated control; #P < .01 and @P < .05 compared with E2-treated cells (P > .05 in all other cases).

Binding of E2 to HUVECs and modulation of the effects of E2 by various compounds.

(A) Saturation curves of the binding of [3H]E2 to cell membranes, alone or in the presence of 100 nM TMX or 100 nM ICI182780. Vertical bars represent SD values. (Inset) Western blot analysis of nuclear (N) and membrane (M) homogenates (10 and 20 μg/lane, respectively), reacted with anti-ERβ antibodies. Molecular mass markers are shown on the right side. (B) Effect of TMX, ICI182780, or HU-210 (100 nM each), of SR141716, CBD, or CAPS (2 μM each), ofl-NAME (400 μM) or of EGTA-am (50 μM) on the activation of AMT by 100 nM E2 or 100 nM E2-BSA (100% = 25 ± 3 pmol × minute−1 × mg protein−1). (C) Effect of the same treatments discussed in panel B on the release of NO and the intracellular calcium ([Ca2+]i) of HUVECs. Values are reported as means ± SD. In all panels, *P < .01 compared with untreated control; #P < .01 and @P < .05 compared with E2-treated cells (P > .05 in all other cases).

Close Modal

or Create an Account

Close Modal
Close Modal